Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: ferrara g. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Ascierto PA, Cioli E, Chiarion-Sileni V, Quaglino P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A, Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C. Ascierto PA, et al. Among authors: ferrara g. Front Oncol. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. eCollection 2023. Front Oncol. 2023. PMID: 36845751 Free PMC article.
International Skin Imaging Collaboration-Designated Diagnoses (ISIC-DX): Consensus terminology for lesion diagnostic labeling.
Scope A, Liopyris K, Weber J, Barnhill RL, Braun RP, Curiel-Lewandrowski CN, Elder DE, Ferrara G, Grant-Kels JM, Jeunon T, Lallas A, Lin JY, Marchetti MA, Marghoob AA, Navarrete-Dechent C, Pellacani G, Soyer HP, Stratigos A, Thomas L, Kittler H, Rotemberg V, Halpern AC. Scope A, et al. Among authors: ferrara g. J Eur Acad Dermatol Venereol. 2024 May 11. doi: 10.1111/jdv.20055. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38733254
Dysgeusia and Chronic Kidney Disease: a Scoping Review.
Sguanci M, Ferrara G, Palomares SM, Parozzi M, Godino L, Gazineo D, Anastasi G, Mancin S. Sguanci M, et al. Among authors: ferrara g. J Ren Nutr. 2024 May 8:S1051-2276(24)00067-0. doi: 10.1053/j.jrn.2024.04.005. Online ahead of print. J Ren Nutr. 2024. PMID: 38729584 Free article. Review.
Convergence and divergence in Kawasaki disease and multisystem inflammatory syndrome in children: results from the COVASAKI survey.
Mastrolia MV, Martini M, Memmini G, Ferrara G, Bernardini R, Peroni D, Consolini R, Marrani E, Agostiniani R, Maccora I, Falorni S, Azzari C, Calabri GB, Pagnini I, Indolfi G, L'Erario M, Trapani S, Simonini G. Mastrolia MV, et al. Among authors: ferrara g. Clin Exp Rheumatol. 2024 Apr;42(4):931-936. doi: 10.55563/clinexprheumatol/l64q51. Epub 2024 Apr 29. Clin Exp Rheumatol. 2024. PMID: 38683206 Free article.
838 results